PTC (NASDAQ: PTC) Q4 2024 Earnings Call Nov 06, 2024, 5:00 p.m. ET ...

With Election Day coming on Nov. 5, staying updated with the rapid flow of news is crucial. Fortunately, watching daily TV ...

Here’s how PBS News will cover election night and the vote-counting to come. At noon, live streaming coverage begins, ...

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

PTC India Financial Services Ltd. is a Public Limited Listed company incorporated on 08/09/2006 and has its registered office in the State of Delhi, India. Company’s Corporate Identification ...

PTC Therapeutics has suffered another setback in its bid to keep its Duchenne muscular dystrophy drug Translarna on the market in Europe. PTC on Friday said the European Medicines Agency's ...

Joel Beatty has given his Buy rating due to a combination of factors related to PTC Therapeutics’ promising developments and the potential of its pipeline. One of the primary reasons for the ...

Loop Capital Markets analyst Yun Kim maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $220.00. The company’s shares closed last Friday at $181.00.

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's PTC 2024 fourth-quarter conference call. (Operator Instructions) I would now like to turn the call over to ...

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on ...

Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsMatt Shimao - Head of Investor RelationsNeil Barua ...